[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"leukaemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:leukaemia":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,51,83,113,164,198],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":46,"leadSponsor":48,"locationsCount":4},"100640447","digitalized-exercise-fit-tool-intervention-for-adolescents-with-blood-cancer-100640447",false,"NCT07621887","Digitalized Exercise Fit Tool Intervention for Adolescents With Blood Cancer","Digitalised Exercise Fit Tool Intervention for Adolescents With Hematologic Cancer","Inclusion Criteria:\n\n* (1) they are 12-18 years old;\n* (2) they had been diagnosed with hematologic cancer such as leukaemia and lymphoma;\n* (3) they are regarded by the responsible physicians as stable, able to conduct PA, and without any PA restrictions,\n* (4) they completed all cancer treatment;\n* (5) they speak Cantonese and read Chinese.\n\nExclusion Criteria:\n\n* (1) Receiving palliative care\n* (2) Have physical or cognitive impairment and learning problems as identified from medical records\n* (3) Identified by physicians that no physical activity should be conducted at the time of recruitment","ALL","12 Years","18 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn if a digitalised Exercise Fit Tool (EFT) mobile application can promote physical activity in adolescents aged 12-18 years who have completed treatment for hematologic cancer (e.g., leukaemia and lymphoma). The main questions it aims to answer are:\n\n1. Is it feasible to conduct a larger randomised controlled trial of the digitalised EFT intervention?\n2. Does the digitalised EFT intervention improve physical activity levels, physical activity self-efficacy, and quality of life at 6 months?\n\nResearchers will compare the digitalised EFT intervention group to a usual care group to see if the mobile application can promote physical activity levels, physical activity self-efficacy, and quality of life in adolescents with hematologic cancer.Participants will:\n\n1. Receive a 20-minute educational session on how to use the mobile application\n2. Use the mobile application to self-assess their appropriate physical activity level and exercise with a virtual coach\n3. Complete questionnaires and wear an accelerometer at 1, 3, and 6 months after enrollment\n4. Attend a 20-30-minute individual interview at 6 months (intervention group only, 10 participants)",[27,28,29,30],"Hematologic Cancer","Leukaemia","Lymphoma","Physical Activity",[32,33,34,35,36,37,38,39],"Adolescents","Cancer","Physical activity","Mobile application","Feasibility randomised controlled trial","Exercise Fit Tool","Quality of life","Digital intervention","NOT_YET_RECRUITING","2026-06-01",{"date":43,"type":44},"2026-06-02","ACTUAL",{"date":41,"type":21},{"date":47,"type":21},"2027-12-31",{"name":49,"class":50},"The Hong Kong Polytechnic University","OTHER",{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":61,"conditions":62,"keywords":68,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":82},"100605812","xdrive-for-florida-based-cancer-patients-100605812","NCT07167381","xDRIVE for Florida-based Cancer Patients","xDRIVE Functional Precision Medicine + Artificial Intelligence Individualized Treatments for Florida-based Cancer Patients With Relapsed\u002F Refractory Cancers","Inclusion Criteria:\n\n* Patients with recurrent\u002Frefractory cancer patients up to age 18 (willing to sign assent if ages 7 - 17 years)\n* -OR- Patients with recurrent\u002Frefractory cancer ≥18 years of age.\n* Patients who have received at least one prior line of standard of care therapy.\n* Patients able to provide treatment and outcome information from previous line(s) of therapy.\n* Patients with sufficient health status to undergo cancer therapy, e.g., Eastern Cooperative Group (ECOG) performance status of 0, 1, or 2 for adult patients.\n* Patients who are scheduled for or have recently undergone a tumor biopsy, excision, or resection.\n* Patients willing to have a blood draw or buccal swab performed for matched normal material for comparison during tumor DNA profiling.\n\nExclusion Criteria:\n\n* Patients who do not have malignant tissue available and accessible, patients where the amount of excised malignant tissue is insufficient material for ex vivo drug testing and\u002For genetic profiling, defined as \\\u003C0.3g for resections or core\u002Ffine-needle biopsies not containing malignant tissue by pathology review, or insufficient malignant tissue in peripheral blood or bone marrow aspirate samples.\n* Patients with insufficient health indicators to undergo therapeutic intervention.",{"count":59,"type":21},210,[24],"Through this study funded by the Florida Cancer Innovation Fund, First Ascent will demonstrate state-wide feasibility of providing xDRIVE Functional Precision Medicine + Artificial Intelligence platform by assessing patient clinical benefit and health economics impacts. As this is a feasibility study, results will be returned to the physician and the physician may use the data to inform the next line of treatment. The investigator will run a prospective single-arm feasibility study providing the xDRIVE FPM AI platform to n = 210+ cancer patients throughout the state of Florida, especially those from underserved populations (pediatric patients and patients in Black, Brown, Hispanic, and rural communities).",[33,63,64,65,28,29,66,67],"Neoplams","Refractory","Recurrence","Solid Tumor Malignancies","Solid Cancers",[69,70],"Functional Precision Medicine","Artificial Intelligence","RECRUITING","2026-05-17",{"date":74,"type":44},"2026-05-19",{"date":76,"type":44},"2025-11-01",{"date":78,"type":21},"2027-04-01",{"name":80,"class":81},"First Ascent Biomedical Inc.","INDUSTRY",2,{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":22,"phases":92,"briefSummary":94,"conditions":95,"keywords":97,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":112},"100632795","phase-1-study-of-ala-101-in-patients-with-cd19-positive-non-hodgkin-lymphoma-and-leukemia-100632795","NCT07518329","Study of ALA-101 in Patients With CD19 Positive Non-Hodgkin Lymphoma and Leukemia.","A Phase 1 Open-Label Dose-Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ALA-101, Allogeneic, Off-the-shelf, CD19-directed CAR-iNKT Cells in Patients With CD19+ Non-Hodgkin Lymphoma and Leukemia","Inclusion Criteria:\n\n* Over 18 years old\n* Confirmed Diagnoses of Confirmed diagnosis of CD19+ non-Hodgkins lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphatic Leukemia or Hairy Cell Leukemia\n* Life Expectancy greater than 3 months\n* Adequate Hepatic and Renal Function\n* Adequate Bone Marrow Function\n* Adequate ECG Vales\n* Agree to use appropriate contraception to avoid becoming pregnant for up to 12 months post treatment and agree not to donate sperm or ova for 12 months post treatment\n\nExclusion Criteria:\n\n* Prior anti-CD1d monoclonal antibody treatment\n* Prior allogeneic stem cell transplant except where the participant is greater than 100 days and does not have Graft Versus Host Disease (uncontrolled)\n* Prior Organ Transplant\n* Previous Malignancy in last 3 years that's active or been treated.\n* Current central nervous system involvement by lymphoma or leukaemia\n* Evidence of Cardiac Dysfunction\n* Active Autoimmune disease requiring systemic immunosuppressive therapy within the past 6 months.\n* Known active hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection.\n* History of Graft Vs Host Disease Grade 2 to 4\n* No active Graft Vs Host Disease following a minimum of 3 months withdrawal from all Graft Vs Host Disease treatments\n* Must not have received systemic anti-cancer therapy for the underlying malignancy within 6 weeks prior to the start of conditioning chemotherapy on Day -6.\n* Participants that have received autologous or allogenic CAR-T cell therapy within 3 months prior to commencing screening.\n* Use of systemic corticosteroids within 15 days of commencement of conditioning chemotherapy on Day -6 or other immunosuppressive drugs within 30 days\n* Recent major surgery (within 4 weeks prior to commencement of conditioning chemotherapy on Day -6) or planned major surgery within 8 weeks following ALA-101 infusion on Day 1.\n* Active infection requiring intravenous antibiotic, antifungal, or antiviral medication or hospital admission within 10 days prior to commencement of conditioning chemotherapy on Day -6\n* Severe (e.g., severe chronic obstructive pulmonary disease, severe Parkinson's disease) or poorly controlled (e.g., hypertension, diabetes, active inflammatory bowel disease) medical condition.\n* Vaccinated with a live vaccine within 28 days prior to commencement of conditioning chemotherapy on Day -6 or planned live vaccination within 6 months following ALA-101 infusion.\n\nAdditional criteria apply.",{"count":91,"type":21},46,[93],"PHASE1","Phase 1 Open-Label Dose-Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ALA-101",[96,28],"Non Hodgkin Lymphoma (NHL)",[98,29,99,100,101,102],"C19+","Leukemia","CART T CELL","iNKT","CAR iNKT","2026-04-06",{"date":105,"type":44},"2026-04-08",{"date":107,"type":21},"2026-04-01",{"date":109,"type":21},"2030-08-30",{"name":111,"class":81},"Arovella Therapeutics Ltd",3,{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":22,"phases":123,"briefSummary":125,"conditions":126,"keywords":140,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":163},"100624518","phase-1-ebnk-001-allogeneic-nk-cells-with-low-dose-il-15--pembrolizumab-in-advanced-solid-tumors-100624518","NCT07410676","EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors","An Open-Label Phase 1\u002F2 Study of EBNK-001, an Allogeneic Natural Killer (NK) Cell Therapy Administered After Cyclophosphamide\u002FFludarabine Lymphodepletion With Low-Dose Interleukin-15, With or Without Pembrolizumab, in Participants With Advanced Solid Tumors","EBNK-ST-001","Inclusion Criteria:\n\n* Age ≥18 years.\n* Histologically confirmed advanced\u002Fmetastatic solid tumor that is relapsed\u002Frefractory after standard therapy (or no standard therapy available).\n* Measurable disease per RECIST v1.1 (or iRECIST if applicable).\n* ECOG performance status 0-1 (or 0-2 as allowed).\n* Adequate organ function (thresholds modeled on NK protocols):\n* Platelets ≥ 75,000\u002FµL; hemoglobin ≥ 9 g\u002FdL; ANC ≥ 1,000\u002FµL (unsupported by growth factors\u002Ftransfusions as defined).\n* eGFR ≥ 60 mL\u002Fmin\u002F1.73m².\n* AST\u002FALT ≤ 3× ULN.\n* Oxygen saturation ≥ 90% on room air (with PFT requirements if indicated).\n* LVEF ≥ 40% (by ECHO\u002FMUGA\u002FCMR).\n* If brain metastases are present, they must be stable for a defined period (example: ≥3 months) and not requiring escalating steroids.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding.\n* Any condition requiring systemic immunosuppression (e.g., \\>5 mg prednisone\u002Fday or equivalent) during dosing window (topical\u002Finhaled may be allowed).\n* Active autoimmune disease requiring systemic immunosuppression.\n* Uncontrolled bacterial, fungal, or viral infection.\n* Receipt of investigational agent within 28 days before first study drug.\n* Live vaccine within 6 weeks prior to lymphodepletion.\n* Known HIV positivity or active hepatitis B\u002FC with detectable viral load (protocol may allow chronic asymptomatic hepatitis depending on risk plan).\n* Known allergy to investigational product components (example: albumin\u002Fhuman or DMSO).\n* Any medical\u002Fsocial condition likely to interfere with study compliance or increase risk.",{"count":122,"type":21},83,[93,124],"PHASE2","This Phase 1\u002F2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of EBNK-001 (allogeneic NK cells) given after lymphodepleting cyclophosphamide\u002Ffludarabine (CY\u002FFLU) and supported with low-dose IL-15, administered either alone or in combination with pembrolizumab in adults with advanced\u002Fmetastatic solid tumors. The study will determine a recommended Phase 2 dose (RP2D) and explore signals of clinical activity using RECIST-based response criteria.",[33,127,28,128,129,130,131,132,133,134,135,136,137,138,139],"Sarcoma","Breast Cancer (Locally Advanced or Metastatic)","Lung Cancer (Diagnosis)","Colorectal Cancer","Melanoma (Skin Cancer)","Bladder Cancer","Kidney Cancer","Pancreatic Cancer Metastatic","Liver Cancer (Primary and Metastatic)","Ovarian Cancer","Esophageal Cancer","Glioblastoma","Non-Melanoma Skin Cancer",[141,142,143,144,145,146,147,148,149,139,150,132,151,152,153,137],"Natural killer cells","NK cell therapy","Solid tumors","IL-15","Breast Cancer","Lung and Bronchus Cancer","Prostate Cancer","Colorectal (Colon and Rectal) Cancer","CAR-T","Melanoma","Kidney (Renal Cell and Renal Pelvis) Cancer","Pancreatic Cancer","Stomach (Gastric) Cancer","2026-02-14",{"date":156,"type":44},"2026-02-18",{"date":158,"type":44},"2026-02-01",{"date":160,"type":21},"2029-12-21",{"name":162,"class":50},"Essen Biotech",1,{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":172,"targetDuration":4,"studyType":22,"phases":174,"briefSummary":176,"conditions":177,"keywords":186,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":4},"100615733","phase-3-a-trial-to-investigate-whether-oral-arsenic-trioxide-is-similar-to-intravenous-arsenic-trioxide-in-pharmacokinetics-safety-and-efficacy-latitudesdkars-301-100615733","NCT07296445","A Trial to Investigate Whether Oral Arsenic Trioxide Is Similar to Intravenous Arsenic Trioxide in Pharmacokinetics, Safety, and Efficacy (LATITUDE\u002FSDKARS-301)","LATITUDE - A Phase 3, Randomized, Open-Label, 3-Cohort, 2-Period, 2-Sequence, Crossover Trial to Evaluate the Pharmacokinetics, Safety, and Efficacy of Oral Arsenic Trioxide Versus Intravenous Arsenic Trioxide for Consolidation Therapy in Participants With Newly Diagnosed, Non-High-Risk, Acute Promyelocytic Leukemia","LATITUDE","Key Inclusion Criteria:\n\n* Participants must have diagnosis of newly diagnosed non-high risk APL with a WBC count at diagnosis ≤ 10,000 cells\u002FµL, completed induction with ATO\u002FATRA and achieved morphologic CR with hematologic recovery\n* Eastern Cooperative Oncology Group performance status ≤2\n* Adequate liver, kidney, and cardiac function\n* Have a life expectancy of at least 9 months\n* Negative serum pregnancy test\n\nKey Exclusion Criteria:\n\n* Diagnosis of relapsed or refractory APL.\n* Fridericia's corrected QT interval (QTcF) \\>450 milliseconds (males) and \\>460 milliseconds (females)\n* Any gastrointestinal (GI) issue likely to affect oral drug absorption\u002Fmetabolism or inability to swallow oral medication\n* Prior malignancy or currently receiving treatment for a non-APL malignancy, with the following exceptions: basal cell or squamous cell skin cancer treated with surgical resection, in situ cervical cancer, localized prostate cancer or breast cancer treated with hormone therapy or surgical resection, or other cancer from which the participant has been disease free for at least 2 years.\n* Pregnant or nursing females or is of reproductive potential and unwilling to comply with contraceptive requirements.\n* Participant has known active or chronic hepatitis B or active hepatitis C (HCV) infection or human immunodeficiency virus (HIV)-positive with detectable viral load.\n\nNote: Additional inclusion\u002Fexclusion criteria may apply, per protocol.",{"count":173,"type":21},120,[175],"PHASE3","LATITUDE: A Phase 3, Randomized, Open-Label, 3-Cohort, 2-Period, 2- Sequence, Crossover Trial to Evaluate the Pharmacokinetics, Safety, and Efficacy of Oral Arsenic Trioxide Versus Intravenous Arsenic Trioxide for Consolidation Therapy in Participants With Newly Diagnosed, Non-High Risk, Acute Promyelocytic Leukemia\n\nRationale:\n\nSDK Therapeutics is developing an oral formulation of arsenic trioxide (ATO) for the treatment of acute promyelocytic leukemia (APL). Patients with APL are usually treated with arsenic trioxide (ATO) through an IV along with all-trans retinoic acid (ATRA) taken by mouth. Receiving ATO through an IV requires patients with APL to go to the hospital a lot and get long treatments (sometimes every day over a year of treatment). This can be hard and uncomfortable. If ATO can be taken by mouth, it would be much easier for patients and their families.\n\nObjective:\n\nThe main objective is to show that the body absorbs the same amount of ATO whether it's taken by mouth or through an IV. Other objectives include checking if ATO taken by mouth works just as well, causes fewer heart problems, is safe, and improves quality of life compared with ATO given through an IV.\n\nMain trial endpoints:\n\nThe main endpoint being measured is how much ATO is in the blood after 5 doses. Another important endpoint is how many patients have no signs of cancer in their blood after 3 rounds of treatment.\n\nSecondary trial endpoints:\n\nOther things being measured include: whether patients stay cancer-free over 2 years; changes in heart rhythm; side effects and lab test results; how patients feel during treatment; how much of ATO is in the blood; and how often patients feel bothered by side effects.\n\nTrial design:\n\nThis is an open-label study, meaning everyone knows which treatment they are getting. Patients will get 4 rounds of treatment, each lasting 8 weeks. After that, patients will have check-ups every 3 months to assess safety and disease status for a total of 2 years.\n\nTrial population:\n\nThe study includes adults and teens (12 years and older) who have APL, are not high-risk, and have already finished the first part of their treatment (induction) with IV ATO and ATRA.\n\nInterventions:\n\nThere are 3 groups in the study:\n\nCohort A: Takes 0.15 mg\u002Fkg Oral ATO for 3 rounds, then switches to 0.15 mg\u002Fkg IV ATO for part of the 4th round.\n\nCohort B: Takes 0.15 mg\u002Fkg IV ATO for 3 rounds, then switches to 0.15 mg\u002Fkg Oral ATO for part of the 4th round.\n\nCohort C: Takes 0.15 mg\u002Fkg Oral ATO for all 4 rounds.\n\nAll cohorts also take 45 mg\u002Fm2\u002Fday ATRA during certain weeks of each round. Doctors will assess efficacy by checking bone marrow samples before and during treatment to see if the cancer is gone. Special lab tests will be used to look for cancer cells. Safety will be assessed by checking for side effects using blood tests, heart tests, physical exams, and other health checks. Quality of life will be assessed by the patients who will fill out surveys about how they feel during treatment and how much the side effects bother them. The study will also look at how often patients need to go to the doctor or hospital; how treatment affects daily life and work; and how satisfied patients are with their treatment.",[178,179,180,181,182,183,28,184,185],"Acute Promyelocytic Leukemia (APL)","Acute Promyelocytic Leukaemia","Acute Promyelocytic Leukemia With PML-RARA","Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA","APL","Acute Promyelocytic Leukemia","Leukemia Acute Promyelocytic Leukemia (APL)","Leukemia, Acute",[187,188],"Oral Arsenic Trioxide","Oral ATO","2025-12-25",{"date":191,"type":44},"2025-12-29",{"date":193,"type":21},"2026-01",{"date":195,"type":21},"2029-01",{"name":197,"class":81},"SDK Therapeutics, Inc.",{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":4,"eligibilityCriteria":204,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":205,"enrollmentInfo":206,"targetDuration":4,"studyType":22,"phases":208,"briefSummary":209,"conditions":210,"keywords":212,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":163},"100616417","randomised-controlled-trial-of-artificial-intelligence-assisted-health-education-100616417","NCT07305337","Randomised Controlled Trial of Artificial Intelligence-assisted Health Education","The Impact of Artificial Intelligence-Assisted Health Education on Patients' Intention to Participate in Clinical Trials: A Cluster-Randomised Controlled Trial","Inclusion Criteria (1) Aged ≥18 years with clear consciousness; (2) Diagnosed with haematological malignancy meeting clinical treatment criteria (WHO criteria); (3) Capable of understanding health education content and possessing basic communication skills; (4) Willing to participate in this study and sign an informed consent form.\n\nExclusion Criteria\n\n(1) Patients with concomitant cognitive impairment, psychiatric disorders, or other conditions severely affecting comprehension; (2) Anticipated hospital stay of less than 3 days, rendering completion of the intervention unfeasible; (3) End-of-life palliative care; (4) Previous participation in other clinical trial education programmes.","90 Years",{"count":207,"type":21},196,[24],"With the rapid advancement of biopharmaceutical technology, clinical trials have become the crucial bridge connecting new drugs from the laboratory to clinical application. Despite the increasing number of clinical trial projects being conducted, nearly all such projects face the common challenge of recruitment difficulties. Subject recruitment constitutes a pivotal stage in clinical trials; the ability to recruit a sufficient number of subjects meeting the trial requirements significantly impacts trial quality and also serves as a key factor influencing trial progress. Hematologic cancers constitute a highly heterogeneous group of malignant diseases originating in the haematopoietic organs and primarily affecting the haematopoietic system. They encompass acute and chronic leukaemias, malignant lymphomas, multiple myeloma, myelodysplastic syndromes, and related disorders. For patients facing treatment decisions, clinical trials represent not only a vital avenue for accessing cutting-edge therapies but also impose heightened demands on their capacity for informed decision-making. Conversational artificial intelligence (AI) based on large language models is rapidly advancing in health education and public health communication. Medical chatbots offer scalable and personalised advantages in delivering health information, promoting behavioural change, and enhancing patient engagement, providing a viable pathway for improving trial literacy and decision support. Accordingly, this study proposes to conduct a clinical trial literacy intervention using AI-powered chatbots among haematological malignancy patients. Through a randomised controlled trial (RCT), it aims to evaluate the impact of AI-assisted health education on patients' understanding of clinical trials and intention to participate. This research seeks to validate the application value of AI technology in health education and explore scalable AI-assisted health education intervention models.",[28,211,29],"Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma",[28,213,29,214,215],"Multiple Myeloma","health education","artificial intelligence","2025-12-12",{"date":218,"type":44},"2025-12-26",{"date":220,"type":44},"2025-06-28",{"date":222,"type":21},"2026-08-30",{"name":224,"class":50},"Zhongnan Hospital"]